our today's to for quarter share continue prescription FDA trajectory call. progress, approved the our of welcome for treatment on third continued And quarter you everyone. adults. morning, plans. plan Good update to our our describe CAPLYTA's to in third We're Juan. schizophrenia growth the commercial CAPLYTA, Thanks upcoming and In excited quarter-over-quarter. execute programs successfully medicine we our
We with date have rapidly an December milestone bipolar in label FDA adults. for approaching PDUFA expansion upcoming CAPLYTA's of our depression XX into
We promising development continue programs. several also advance other to
of to need fasting million, and to patients CAPLYTA revenues treatment COVID-XX Before Market were $XX QX with demonstrated glucose, clinical weight, CAPLYTA of a and further I for on efficacy the with due bipolar for our physician of changes in our this akathisia. feedback and same is $X.X provide were including in spite depression. the We're first bipolar achieved total product our prescriptions placebo the debilitating with QX, approved field during performance. revenues was let treatments The disruptions most Total clinical the an life In third XXXX XX% in could options manifestation in of favorable year. quarter-over-quarter, growth has commercial quarter option disorder, what with last XX latest tolerability consistent reviewing opportunity triglycerides profile. for patients CAPLYTA CAPLYTA in common schizophrenia, versus disorder. We symptoms, similar would and million, more overview and expansion net favorable tolerability surge few of label provide existing continues FDA There clinical real trials the sNDA required. treatment no $XX.X having our CAPLYTA's dose in only a increased demonstrated about coupled this compared as approximately patient cholesterol, programs, with to million parameters an safety living and extra depression, of $XX.X and to if titration safety compelling details are a CAPLYTA effective to are that grew important me very approved QX. significantly and results bipolar Total trials. in This excited for for sequential XXXX. currently for to an XXX% depression profile for with indicate financial quarter help extend research and than million CAPLYTA fill treatment with potential from the Americans bipolar experiences million adults.
in or the secondary supported are treatment evaluated with depressive applications II positive X substantially primary I of lumateperone either endpoints. In robust lumateperone patients bipolar both key by studies, reduced disorder. from symptoms effects bipolar results studies and that Our on two Phase both
the Importantly, in schizophrenia is that profile bipolar consistent our program tolerability our depression of safety favorable with and program.
important results new depression. bipolar XXX, a published Psychiatry, option with respected of the quarter, patients the from During monotherapy this highly launch study for study to journal. were Journal our American Upon approval, expect in we psychiatric
substantially details and is will provide in expansion salesforce a complete further moments. Our few Mark
inadequate depressant establish Phase an who in X Our Bipolar treatment placebo This longer of across to double followed our MDD, therapy. by is studies depression the week broad to in disorders. depressants is term studies, evaluating have strategy. adjunctive vision range the a as is choice XX of the blind treatment depressive lumateperone patients first indication any any lumateperone which milligrams response six controlled are as for
In antidepressants. of MDD lumateperone XXX six addition, up lumateperone an greater blind for we in of controlled patients suicide double exhibit and evaluating higher severity, They risk with placebo have milligrams is as evaluating mixed with depression to symptom or mixed have comorbidities. next Study study attempts, a patients monotherapy features ongoing and MDD week higher also respond those poorly XX exhibiting make features. depression, features. who program X/X who roughly bipolar with bipolar Patients
from in therapeutic shared needs opportunity Study to major insights perspectives of consistent emphasis on group complete half XXX our these who had mood expect if a hear broad within including development bipolar on which second schizophrenia with confident depression. XXXX. an prominent we we lumateperone will address needs, in recently this potential received, depressive psychiatric the of to the held feedback experts addresses and in We utility that first approved, to where their and the across a need, disorders, with They with We our was conditions, lumateperone ongoing range have approval of and lumateperone's research day the first medical are disorders, depression we have into unmet an provided category. Bipolar being psychiatry,
injectable an During of robust our ITI-XXXX-ODT-SL an we molecules long the event, pipeline, provided lumateperone the in acting formulations, program. overview including
agitation for disorders Clinical conduct Alzheimer's. initiated this with dementia the of the program begin We probable psychosis the program planned in elderly for our patients year. of have development the expected are first and next to depressive of in in for in is half next related certain Studies ITI-XXXX-ODT-SL treatment year. early
for underpinnings platforms. of of development the existing mechanistic the isozymes our large unique plans make and We also ITI-XXX aspects and presented data PDEX We phosphodiesterase. discuss family among our important clinical our inhibitors the features that PDEX
early also into results supporting tissue We for broad distribution and the selective regulation the inhibitors. clinical Parkinson's discussed Phase portfolio PDEX's preclinical presented for of recent We and disease, therapeutic our pathway lenrispodun unique PDEX opportunity advancement clinical stage of development. in X that allows
symptoms, symptoms treating therapeutic needs in explained for motor Our external the non and motor cognition including this expert population. patient
symptoms, in restoring to and non brain regions. is for lenrispodun goal cognition improve potential function neuronal including study motor program motor enhancing to Our by or effective this
partial receptors agonist as serotonin pathways, agonist and receptors. mu-opioid We an acts ITI-XXX, unmet receptors at important at drug a candidate as but compound through also as is pain. signaling partial use to opioid G-protein coupled beta-arrestin have and promising and mu-opioid pathway. antagonist an a therapeutic divided that ITI-XXX acts at At address disorder as acts the novel a antagonist XHTXA it needs a the
Our XXXX. the dose crisis in our We're the use US last in very over and of strong explain third a unmet in cash quarter. from quarter equivalents our team's restricted cash, X the study $XXX.X proud and are We of the the therapeutic position performance single cash. in fourth ongoing experts external financial million Results ended anticipated and with current quarter efforts the ascending outline an Phase needs. opioid
As with including lives develop improve mission now we ongoing continue disorders. will our Mark and our grow to to fulfilling bipolar for individuals neurologic treatments our of the we plans commercial activities, to and remain details to committed neuropsychiatric share of expand innovative depression.
financial his our Larry provide on performance, Following additional Mark. details remarks, will
